TABLE 1.
Ongoing clinical trials investigating inhibitors of signaling pathways as treatment for OA.
| Intervention | Mechanism | Targets | Joint | Phase | NCT No. | Recruitment Status |
|---|---|---|---|---|---|---|
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | knee | Phase 3 | NCT04520607 | Active, not recruiting |
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | knee | Phase 3 | NCT04385303 | Completed |
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | knee | Phase 3 | NCT03928184 | Completed |
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | knee | Phase 2 | NCT03706521 | Terminated |
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | knee | Phase 2 | NCT03122860 | Completed |
| Lorecivivint (SM04690) | Wnt signaling pathway inhibitor | Wnt signaling pathway | Not given | Phase 2 | NCT02536833 | Completed |
| SAR-113945 | I-kappa B kinase inhibitors | NF-κb | knee | Phase 2 | NCT01598415 | Completed |
| SAR-113945 | I-kappa B kinase inhibitors | NF-κb | Not given | Phase 1 | NCT01113333 | Completed |
| SAR-113945 | I-kappa B kinase inhibitors | NF-κb | knee | Phase 1 | NCT01463488 | Completed |
| SAR-113945 | I-kappa B kinase inhibitors | NF-κb | knee | Phase 1 | NCT01511549 | Completed |
| PH-797804 | p38 MAPK inhibitor | p38 MAPK | Not given | Phase 2 | NCT01102660 | Completed |